Gilead and Arcus want you to believe again in TIGIT. But mixed ARC-7 data are rolling out to a tough crowd

Bioregnum Opinion Column by John Carroll

Roche let the air out of the TIGIT party balloon with a pair of crushing Phase III failures. Now Gilead $GILD and Arcus

Click to view original post